Cambridge Healthtech Institute第3屆

Oncolytic Virus Immunotherapy

( 溶瘤病毒免疫療法 )




Coverage will include, but is not limited to:

Latest updates and future directions in oncolytic virus immunotherapy

  • Update on recent deals, science and collaborations - what are the market dynamics - types of viruses (Herpes, Adeno, Vaccinia)
  • Feedback from big pharma, Pfizer, Amgen's post T-Vec OV portfolio
  • What needs to happen to take OVs forward
  • Update from companies with late-stage products/approvals - post-market approvals

Oncolytics in an era of combination therapies

  • Are combinations the only way forward for oncolytics?
  • Examples of successful combination models - checkpoints, CAR Ts, kinase inhibitors, alternative to checkpoints, antibodies
  • Issues when combining OVs - feedback on trials
  • Evidence to support role of oncolytics as monotherapies?

Improving OV potency, targeting and efficacy

  • Engineering strategies to improve efficacy and specificity - highly armed OVs
  • New virus, mechanism of actions
  • Tumor targeted delivery - latest from Ignite
  • Impact of tumor microenvironment - vascularization

Improving delivery and administration

  • Oncolytics as a single shot vs. multiple shots - mechanisms of action, evidence-based medicine
  • IV vs. systemic - dosage, delivery, delivery when combining with PD-1s
  • Evidence to support systemic route, what data is available

Oncolytics in development: Update on major clinical and preclinical therapies

  • Clinical updates - results, safety, efficacy issues, patient selection, setting endpoints, presenting data to physicians
  • Lessons learned in the clinic - translational strategies, novel preclinical models, biomarkers
  • Regulatory expectations -what to submit to regulators, data to include, feedback

* 活動內容有可能不事先告知作更動及調整。

Choose your language